Table 1 Patient characteristics.

From: Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort

Characteristic

Overall, N = 151a

NCR, N = 67a

PIF, N = 61a

UR/RR, N = 23a

Year of HCT

 Before 2015

83 (55%)

35 (52%)

35 (57%)

13 (57%)

 During/after 2015

68 (45%)

32 (48%)

26 (43%)

10 (43%)

Treatment center

 MSK

81 (54%)

27 (40%)

34 (56%)

20 (87%)

 Stanford

70 (46%)

40 (60%)

27 (44%)

3 (13%)

Age at HCT

56 (22, 73)

57 (25, 72)

50 (22, 73)

62 (26, 72)

Sex

 Female

63 (42%)

22 (33%)

28 (46%)

13 (57%)

 Male

88 (58%)

45 (67%)

33 (54%)

10 (43%)

HCT-CI

 0–2

67 (45%)

30 (45%)

26 (44%)

11 (50%)

 3–5

68 (46%)

34 (51%)

25 (42%)

9 (41%)

 ≥6

13 (8.8%)

3 (4.5%)

8 (14%)

2 (9.1%)

 Unknown

3

0

2

1

HLA

 MRD

52 (34%)

27 (40%)

16 (26%)

9 (39%)

 MUD*

65 (43%)

28 (42%)

29 (48%)

8 (35%)

 MMUD

28 (19%)

10 (15%)

13 (21%)

5 (22%)

 Haploidentical

6 (4.0%)

2 (3.0%)

3 (4.9%)

1 (4.3%)

Donor–recipient CMV serostatus

 Negative-Negative

36 (24%)

22 (34%)

9 (15%)

5 (23%)

 Negative-Positive

39 (26%)

10 (15%)

22 (36%)

7 (32%)

 Positive-Negative

16 (11%)

9 (14%)

4 (6.6%)

3 (14%)

 Positive-Positive

57 (39%)

24 (37%)

26 (43%)

7 (32%)

 Unknown

3

2

0

1

Extramedullary disease

12 (7.9%)

6 (9.0%)

3 (4.9%)

3 (13%)

Recipient CMV

 Negative

53 (35%)

31 (46%)

13 (21%)

9 (39%)

 Positive

98 (65%)

36 (54%)

48 (79%)

14 (61%)

Percent BM Blast

10 (0, 94)

10 (0, 90)

11 (0, 51)

8 (2, 94)

 Unknown

1

1

0

0

KPS (<90 vs. ≥90)

 <90

82 (54%)

29 (43%)

37 (61%)

16 (70%)

 ≥90

69 (46%)

38 (57%)

24 (39%)

7 (30%)

Graft type

 Unmodified BM

10 (7.0%)

3 (4.8%)

4 (6.8%)

3 (14%)

 Unmodified PBSC

127 (89%)

58 (92%)

52 (88%)

17 (81%)

 CD34+ selected

6 (4.2%)

2 (3.2%)

3 (5.1%)

1 (4.8%)

 Unknown

8

4

2

2

Presence of circulating blasts

50 (33%)

23 (34%)

20 (33%)

7 (30%)

Pre-HCT Albumin (g/dl)

3.40 (2.10, 4.60)

3.50 (2.10, 4.60)

3.30 (2.30, 4.20)

3.50 (2.90, 4.20)

 Unknown

3

2

1

0

Pre-HCT Ferritin (ng/mL)

1,392 (109, 9,026)

1,378 (207, 9,026)

1,763 (109, 7,700)

924 (598, 4,804)

 Unknown

103

48

44

11

Disease risk at diagnosis (AML)

 Favorable

3 (2.4%)

2 (3.8%)

0 (0%)

1 (4.3%)

 Intermediate

46 (36%)

16 (31%)

18 (35%)

12 (52%)

 Poor

78 (61%)

34 (65%)

34 (65%)

10 (43%)

 Unknown

24

15

9

0

Complex karyotype at diagnosis

31 (21%)

18 (27%)

12 (20%)

1 (4.3%)

Monosomal karyotype

16 (13%)

9 (19%)

6 (13%)

1 (4.3%)

 Unknown

32

19

13

0

GVHD prophylaxis

 Calcineurin inhibitor/Methotrexate

87 (61%)

32 (50%)

39 (70%)

16 (73%)

 Calcineurin inhibitor/Mycophenolate Mofetil

24 (17%)

14 (22%)

7 (13%)

3 (14%)

 Cyclophosphamide based

7 (4.9%)

3 (4.7%)

2 (3.6%)

2 (9.1%)

 Other

24 (17%)

15 (23%)

8 (14%)

1 (4.5%)

 Unknown

9

3

5

1

Intensity

 MAC

96 (64%)

40 (60%)

43 (70%)

13 (57%)

 RIC/NMA

55 (36%)

27 (40%)

18 (30%)

10 (43%)

  1. IQR interquartile range, NCR primary induction not in complete remission, PIF primary induction failure, UR untreated relapse, RR refractory relapse, MAC myeloablative conditioning, RIC reduced intensity conditioning, NMA non-myeloablative conditioning, MSK Memorial Sloan Kettering Cancer Center, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, MRD matched related donor, MUD matched unrelated donor, MMUD mismatched unrelated donor, CMV cytomegalovirus, KPS Karnofsky Performance Scale, BM bone marrow, PBSC peripheral blood stem cells, HCT hematopoietic stem-cell transplantation.
  2. an (%); Median (Range).
  3. *Matched donor was defined as at least an 8/8 HLA allele level.
Back to article page